T1000	Negation 420 423	not
E1000	Negation:T1000 Scope:T1001
T1001	Span 420 481	not shown) as previously demonstrated (Jorritsma etal., 2003)
T1002	Negation 384 387	not
E1001	Negation:T1002 Scope:T1003
T1003	Span 384 429	not only in naive CD4+ Tcells (data not shown
T1004	Speculation 945 952	whether
E1002	Speculation:T1004 Scope:T1005
T1005	Span 945 1106	whether ERK1 and ERK2 activation was required for the induction of IL-10 in Th1 cells by using U0126 (Figure5C), a compound that blocks downstream ERK activation
T1006	Speculation 850 857	whether
E1003	Speculation:T1006 Scope:T1007
T1007	Span 850 921	whether they were restimulated with high or low antigen dose (Figure5B)
T1008	Negation 2244 2246	no
E1004	Negation:T1008 Scope:T1009
T1009	Span 2244 2298	no effect on IL-10 production was observed (FigureS5B)
T1010	Negation 1920 1923	not
E1005	Negation:T1010 Scope:T1011
T1011	Span 1920 1965	not MEK5 (Bain etal., 2007; Mody etal., 2001)
T1012	Negation 2440 2443	not
E1006	Negation:T1012 Scope:T1013
T1013	Span 2440 2494	not the activation of the p38 or the GSK3beta pathways
T1014	Speculation 2189 2191	or
E1007	Speculation:T1014 Scope:T1015
T1015	Span 2189 2286	or the GSK3beta inhibitor, CT99021 (Bain etal., 2007), no effect on IL-10 production was observed
T1016	Speculation 2314 2323	suggested
E1008	Speculation:T1016 Scope:T1017
T1017	Span 2314 2494	suggested that IL-10 production by Th1 cells in response to high antigen dose and IL-12 requires ERK1 and ERK2 signaling, but not the activation of the p38 or the GSK3beta pathways
